Global Health Science Institute

What it reported doing in 2025

CORE IMPACTS FOR THE YEAR 2025 Index of Major Program Accomplishments Overview While we secure capital to construct our 7,500 sq. ft. biomedical and engineering development facility, we have focused on translational science and engineering: publishing, building working biomedical tools, and developing human-relevant research systems using microcontrollers, 3D modeling, and AI technologies. Our organization designs and builds human-centered biomedical tools that replace fragile, high-cost laboratory systems and reduce reliance on animal models. We emphasize practical innovation - technologies that can be manufactured, repaired, and adapted locally using microcontrollers, 3D-printed components, laser-cut materials, and simulation-driven design. This allows us to build affordable, reproducible tools aligned with real-world patient care - not just theoretical laboratory success. A. Major Cancer Publication - Advancing Understanding in RAS-Driven Disease In collaboration with researchers from the University of Texas-El Paso and New Mexico State University, our team published a 39-page biomedical journal article in Biology (2025, Vol. 14, Issue 8, Article 936): "Research Challenges in Stage III and IV RAS-Associated Cancers: A Narrative Review of the Complexities and Functions of the Family of RAS Genes and Ras Proteins in Housekeeping and Tumorigenesis." The core message is simple and sobering: after more than 50 years of global research into RAS-driven cancers, late-stage patients still lack reliable therapeutic options. This paper identifies the major biological and translational barriers preventing progress and calls for practical, implementation-focused innovation rather than incremental repetition of prior work. Autodesk Inventor Pro was used to support scientific visualization and pathway modeling. B. Human Adaptive Response Emulator (HARE) We began developing the Human Adaptive Response Emulator (HARE) - a human-relevant biology platform designed to generate decision-quality data before medical technologies reach clinical trials. Many products perform well in animal models but fail in humans because: * animal disease models do not faithfully replicate human disease * toxicity responses differ across species * animal immune systems provide misleading safety signals HARE addresses these failure points directly by operating in human-derived cells and human-relevant signaling environments, thereby evaluating disease behavior, toxicity, and immune response in systems that reflect real human biology. This work advances our mission to develop ethical, efficient, and patient-centered biomedical tools and to help reduce clinical trial failures driven by animal-based inference. C. Autonomous UV-C Floor Decontamination System (AUF-DS) We are developing an autonomous UV-C floor-decontamination robot for healthcare, laboratory, and community environments where biological contamination risk is high but staffing and resources are limited. Traditional cleaning depends on labor-intensive processes, chemical disinfectants, and inconsistent coverage. Our goal is to design a cost-efficient, microcontroller-based platform that autonomously navigates indoor spaces and delivers controlled UV-C exposure to floor surfaces - reducing microbial burden without chemical residue. The system is being designed using open-architecture principles, so nonprofit hospitals, public laboratories, and educational institutions can reproduce or adapt the technology without proprietary lock-in or high licensing costs. During this reporting period, we focused on concept design, navigation strategy, safety shielding, and controlled UV-C exposure management. Future phases will include validation testing and publication of implementation guidance to support adoption in resource-limited environments. D. Plexiglass Isotope Column Holders We designed and fabricated precision plexiglass isotope-column holders to improve the stability and reproducibility of column-based separ

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 100%; rating input score 100
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 91.7%; rating input score 92; 20th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Limited
• Grant itemization coverage: 0%; rating input score 0; 20th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 4 of 7 controls in place; rating input score 57
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Fail
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: 0%; rating input score 35; 35th percentile among comparable filings
• Total-asset coverage ratio: 0; rating input score 1; 1st percentile among comparable filings
• Liabilities to assets ratio: Limited
• Officer compensation ratio: 0%; rating input score 67; 67th percentile among comparable filings

Growth

• Program expense growth: 25.3% per year; rating input score 100; 87th percentile among comparable filings
• Revenue growth: 25.3% per year; rating input score 100; 90th percentile among comparable filings
• Asset growth: Limited